

miR-34a is downregulated in human osteosarcoma stem-like cells and promotes invasion, tumorigenic ability and self-renewal capacity

YONGGEN ZOU¹, YUANSHUAI HUANG², JIEXIANG YANG¹, JIAN WU¹ and CHENG LUO¹

¹Department of Orthopedics, The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University;

²Department of Transfusion, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, P.R. China

Received December 3, 2015; Accepted November 25, 2016

DOI: 10.3892/mmr.2017.6187

Abstract. MicroRNA-34 (miR-34), in particular miR-34a, has a negative regulatory effect on osteosarcoma cell proliferation, migration and invasion. Notably, it is also a post-transcriptional regulatory factor of (sex determining region Y)-box 2 (Sox-2), which is required for osteosarcoma cell self-renewal and tumorigenesis. As a direct regulator of Sox-2, miR-34a has been hypothesized to be greatly associated with the regulation of malignancies in osteosarcoma. To investigate the role of miR-34a in the malignancies of osteosarcoma, reverse transcription-quantitative polymerase chain reaction was performed to detect the expression level of miR-34a in osteospheres. The results revealed that the miR-34a, b and c were suppressed in osteosarcoma stem-like cells (OSCs) and osteospheres. The introduction of miR-34a mimics and short hairpin (sh)RNA targeting Sox-2 mRNA (shSox-2) in human OSCs markedly reduced their transformation properties *in vitro* and their capacity to form tumors in soft agar. Furthermore, the epigenetic expression of miR-34a and shSox-2 inhibited the expression of the stem cell marker, stem cell antigen-1 and led to the failure of osteosphere formation, respectively. The data of the present study indicated that the inhibitory role of miR-34a on tumor growth and metastasis of osteosarcoma may function by reducing the maintenance of osteosphere self-renewal capacity, elimination of tumorigenic ability and invasion of osteosarcoma *in vitro*. These findings may provide the basis for a novel therapeutic target of osteosarcomas based on inducing the expression of miR-34a.

Introduction

Osteosarcoma is the most life-threatening type of malignant primary bone tumor, with high incidence rates in children and adolescents (1). Despite the combination of chemotherapeutics and aggressive surgery, there have been no significant improvements in the long-term survival rates of patients due to the presence of metastases at initial diagnosis and of chemoresistance (2). Several factors lead to chemoresistance, including activation of the Wnt- β -catenin pathway or upregulated microRNAs (miRNAs), which target apoptotic factors (3,4). In addition, increasing evidence has supported the hypothesis that a small cell sub-culture presenting with stem-like properties is responsible for cancer relapse (5), which suggests the existence of osteosarcoma stem-like cells (OSCs).

miRNAs are a class of endogenous, noncoding RNAs, which are 19-21 nucleotides in length (6). Although the coding genes of miRNAs constitute ~1% of the entire genome, they have important regulatory effects on various genes at the post-transcriptional level by directly or indirectly targeting the coding sequence or non-coding sequence of their mRNAs. In total, the extensive regulatory role of miRNAs includes >30% of all human genes (7). Due to their multi-target property, their potential regulatory role involves almost all physiological processes, including tumor progression and tumor suppression. Previous studies have identified miR-21, 155, 27, 96, 182 and 128 as oncogenes, and miR-125, 205, 27, 17, 206 and 145 have been identified as tumor suppressor genes (8-10), suggesting their importance in tumor initiation and progression.

miR-34a, as a member of the conserved miR-34 family, is a direct transcriptional target of the p53 tumor suppressor (11). It is important in regulating cell cycle arrest, cell senescence, apoptosis and other biological behaviors in a p53-dependent manner (12). The effects of miR-34a on osteosarcoma growth and metastasis have been evaluated *in vitro* and *in vivo* (13). The overexpression of miR-34a inhibits the growth and metastasis of osteosarcoma cells *in vivo* and *in vitro*. miR-34a promotes the induction of pluripotent stem cell generation by post-transcriptionally targeting (sex determining region Y)-box 2 (Sox-2) mRNA, which is a transcription factor of the HMG domain family and has important effects on embryonic development, and maintaining the pluripotency and

Correspondence to: Dr Yonggen Zou, Department of Orthopedics, The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, 16 Chunhui Road, Luzhou, Sichuan 646000, P.R. China
E-mail: 13649044264@126.com

Key words: microRNA-34, osteosarcoma, stem cell antigen-1, (sex determining region Y)-box 2, osteosphere

self-renewal capacity of stem or stem-like cells (14,15). Further confirmation that Sox-2 is necessary for the self-renewal of the osteoblast lineage suggests the potential role of miR-34a in regulating not only proliferation and metastasis, but also the self-renewal capacity of OSCs (16).

In the present study, the role of miR-34a in OSCs was investigated. The data showed that miR-34a was downregulated in U-2OS-derived stem-like cells, compared with monolayer cells. The epigenetic expression of miR-34a in OSCs decreased colony formation and self-renewal capacity, which was similar to the effects of the expression of short hairpin (sh) RNA targeting Sox mRNA (shSox). Consistently, these cells showed upregulation of the osteogenic markers, Runx-related transcription factor 2 (Runx-2) and Collagen type I. In addition, the expression of miR-34a and shSox suppressed the expression of Sox-2 directly and stem cell antigen-1 (Sca-1) indirectly.

Materials and methods

Cell line and osteospheres. The U-2OS human osteosarcoma cell line was purchased from American Type Culture Collection (Manassas, VA, USA). The cells were routinely cultured in Dulbecco's modified Eagle's medium (DMEM)/F12 medium (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA), supplemented with 10% fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc.) in a humidified atmosphere of 5% CO₂ in air at 37°C.

For culturing osteospheres, 1×10⁶ U-2OS cells were suspended in DMEM/F12 medium without serum, supplemented with 2% B-27 (Thermo Fisher Scientific, Inc.), 20 ng/ml basic fibroblast growth factor (b-FGF) and 100 ng/ml epidermal growth factor (EGF). The cultures were maintained at 37°C in air with 5% CO₂.

Immunofluorescence and immunoblotting. For detection of the target protein, the cells adhered to the well were washed with PBS containing 0.1% Triton X-100 (PBST) and incubated with rabbit anti-Sca-1 antibody (catalog no. ab124688; 1: 1,000; Abcam, Cambridge, UK) labeled with FITC dye at a final concentration of 10 µg/ml overnight at 4°C. The slides were rinsed three times with PBST, stained with DAPI (Thermo Fisher Scientific, Inc.) and mounted. Fluorescence was visualized and images were captured using an Olympus IX-71 inverted microscope (Olympus Corporation, Tokyo, Japan).

For the immunoblotting analysis of the protein of interest, the cells were suspended in lysis buffer containing 200 mM NaCl, 50 mM Tris (pH 7.4), 5 mM EDTA and 0.5% NP-40, and placed on ice for 15 min. The cells were centrifuged and collected, 2,000 × g for 10 min at 4°C. The supernatant was collected and SDS-PAGE loading buffer was added. The concentration of lysate was detected by BCA assay (Sigma-Aldrich, Merck Millipore, Darmstadt, Germany). The lysate was boiled at 100°C for 15 min. The prepared samples were fractionated by electrophoresis on Tri-Tricine polyacrylamide gels (total protein, 50 µg per lane). The blots were transferred onto PVDF membranes. Membranes were blocked with 5% BSA (Sigma-Aldrich, Merck Millipore) in TBST (20 mM Tris, 150 mM NaCl, containing 0.3% Tween-20, pH 7.4) for 30 min. Membranes were then incubated with

mouse anti-SOX-2 antibody (catalog no. ab171380; 1:1,000; Abcam) or mouse anti β-actin antibody (catalog no. ab8227; 1:1,000; Abcam) in TBST with 1% BSA (Sigma-Aldrich, Merck Millipore) at room temperature for 1 h. Following 3 washes with TBST, the membranes were incubated with anti-mouse IgG horseradish peroxidase-conjugated secondary antibody (catalog no. ab6785; 1:5,000; Abcam) for 1 h at room temperature. Following 3 washes with TBST, membranes were exposed to Clarity enhanced chemiluminescence (ECL) reagent (Thermo Scientific Fisher, Inc., Waltham, MA, USA).

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis. Total RNA from the monolayer or osteosphere cells derived from the U-2OS cells was isolated in TRIzol reagent (Thermo Fisher Scientific, Inc.) and 1 µg of RNA was reverse transcribed using an miScript reverse transcription kit (Qiagen, Inc., Valencia, CA, USA). The synthesized cDNA was analyzed by qPCR analysis using SYBR Green qRT-PCR assays on an ABI 7500 system (Applied Biosystems; Thermo Fisher Scientific, Inc.). The sequences of primers used were as follows: Forward, 5'-GCCGAGTGGAAACTTTTGTCG-3' and reverse 5'-GGCAGCGTGTACTTATCCTTCT-3' for Sox-2 and forward 5'-CATGTACGTTGCTATCCAGGC-3' and reverse, 5'-CTCCTTAATGTCACGCACGAT-3' for β-actin. The cycling variables were set as follows: 95°C for 10 min, followed by 40 cycles of 95°C (30 sec), 55°C (30 sec) and 70°C (30 sec). Human U6 RNA was used as an internal control for RNA normalization. All reactions were performed in triplicate.

A TaqMan MicroRNA Assay protocol was performed (Applied Biosystems, Thermo Fisher Scientific, Inc.), for the detection of miRNA, according to the manufacturer's protocol, and snoU6 RNA was used as an internal control.

Construction and transfection of the miR-34a precursor expression vector (pre-miR-34a). The pre-miR-34a was inserted into an enzyme site of the pEZX-MR04 vector (Genecopoeia, Guangzhou, China) for expressing the miRNA precursor. A scrambled sequence of the miR-34a precursor was inserted into the same sites of the pEGP-MR04 vector and used as a negative control. According to the manufacturer's protocol, the plasmid was transfected into the U-2OS cells using Lipofectamine® 2000 (Thermo Fisher Scientific, Inc.).

Self-renewal assay. Osteospheres derived from the U-2OS were maintained in serum-free medium DMEM/F12, supplemented with b-FGF, EGF and B-27. The single cell suspension was harvested by centrifugation (1,000 × g for 10 min at 4°C) and finally re-suspended in serum-free DMEM/F12, containing 100 U/ml penicillin/streptomycin, 2 mM L-glutamine, 10 µg/ml heparin, 20 ng/ml b-FGF, 100 ng/ml of EGF and 2% B-27 supplement (17,18). To assess self-renewal capacity, the osteospheres were chemically dissociated and suspended in serum-free medium. The suspended cells (1×10⁵) were then plated in 6-well plates. Following incubation for 2 weeks at 37°C, proliferating osteospheres >40 µm in diameter were counted under a phase contrast microscope and considered to be the clonogenic capacity of the OSCs.




Figure 1. Relative expression of miR-34a, b and c in OSCs and U-2OS cell monolayers, detected using SYBR Green reverse transcription-quantitative polymerase chain reaction analysis. (A) Culture of OSCs in serum-free medium on days 3, 10 and 14. (B) Representative photomicrographs reveal the staining of marker antigens Sox-2 (red) and Sca-1 (green). (C) Average expression levels of miR-34a, b and c in OSCs, compared with those in monolayer cells. * $P < 0.05$ ($n = 3$). miR, microRNA; OSCs, osteosarcoma stem-like cells; Sox-2, (sex determining region Y)-box 2; Sca-1, stem cell antigen-1.

In vitro tumorigenicity assay using soft agar. To assess anchorage-independent growth, 1×10^4 cells were suspended in semi-solid medium (DMEM/F12 without FBS, containing 0.3% low-melting agarose) with a 0.6% low-melting agarose underlay in 6-well plates and incubated at 37°C . After 2-3 weeks, the colonies were counted under a X71 (U-RFL-T) fluorescence microscope (Olympus, Corporation, Tokyo, Japan).

Invasion assay. To examine cell invasion, 1×10^5 cells were plated in the upper compartment of Transwell chambers (Corning Incorporated, Corning, NY, USA), which had been pre-coated with Matrigel (Thermo Fisher Scientific, Inc.), and incubated in DMEM/F12 at 37°C . Medium containing 10% FBS was added to the lower compartment of the chamber. After 24 h, the cells were stained using 0.05% crystal violet and counted under a phase contrast microscope. All experiments were performed in triplicate.

Statistical analysis. Each experiment was performed at least three times and all values are reported as the mean \pm standard deviation. Student's t-test was used to analyze the difference between groups. $P < 0.05$ was considered to indicate a statistically significant difference. Statistical analysis was performed using SPSS software version 11.5 (SPSS, Inc., Chicago, IL, USA).

Results

miR-34 is downregulated in human OSCs. It has been suggested that osteosarcoma may contain a sub-population of tumor-initiating stem cells (19). To determine the presence of putative OSCs in the present study, the suspended U-2OS cells were incubated in serum-free medium in anchorage-independent conditions, as described above. After 3 days, the cells started to form colony-like structures and formed spheres of $\sim 100 \mu\text{m}$ in diameter (Fig. 1A) after 14 days. As a previous report demonstrated the presence of Sox-2 in U-2OS cells and the presence of sca-1 in OSCs as a marker of stem cells (20), Sox-2 and Sca-1 were stained using Alex fluor 488 or 567-labeled antibody and were found to be present within one sphere (Fig. 1B). Notably, not all cells in one sphere expressed Sox-2 and Sca-1 simultaneously. To examine the differences in the expression of miR-34 between U-2OS cells and OSCs, OSCs derived from U-2OS cells were used to evaluate the expression levels of miR-34a, miR-34b and miR-34c using RT-qPCR analysis. The results showed that, compared with the U-2OS cells, the expression levels of miR-34a, miR-34b and miR-34c were significantly downregulated ($P \leq 0.05$; Fig. 1C).

Sox-2 is suppressed in U-2OS cells due to the upregulation of miR-34a. It has been reported that miR-34a inhibits the proliferation and metastasis of osteosarcoma cells, including U-2OS




Figure 2. Sox-2 and Sca-1 are expressed at low levels in osteosarcoma-derived form U-2OS cells. (A) mRNA (left) and protein (right) levels of Sox-2 were analyzed using RT-qPCR and semiquantitative western blot analyses. * $P < 0.05$ ($n = 3$). (B) Effects of miR-34a mimic- or shSox-2-transfected osteosphere cells on Sox-2 and Sca-1 were detected using RT-qPCR and semiquantitative western blot analyses. * $P < 0.05$ ($n = 3$). miR, microRNA; Sox-2, (sex determining region Y)-box 2; Sca-1, stem cell antigen-1; RT-qPCR, reverse transcription-quantitative polymerase chain reaction; sh, short hairpin.

cells (21). The downregulation of miR-34a in osteospheres indicates the potential regulatory mechanism in promoting tumorigenesis. As the post-transcriptional target of miR-34a, the mRNA and protein levels of Sox-2 in osteospheres were compared with the U-2OS cell monolayer. The results showed that the mRNA and protein levels of Sox-2 were higher in the osteospheres, compared with the U-2OS cells (Fig. 2A). To determine the role of miR-34a in the regulation of Sox-2, miR-34a mimics, scrambled miR-34a mimics, shSox-2 and scrambled shRNA were introduced into the U-2OS cells, respectively. As expected, the expression of shSox-2 down-regulated the mRNA and protein levels of Sox-2, whereas the scrambled shRNA and scrambled miR-34a mimics did not (Fig. 2B). Notably, transfection of the cells with miR-34a mimics did not affect the mRNA expression of Sox-2, however, it significantly decreased its protein level, consistent with a previous report (22). Furthermore, as a stem cell marker regulated by Sox-2, the same trend was observed for Sca-1.

miR-34a reduces the tumorigenic ability and self-renewal capacity of osteospheres by targeting Sox-2. To determine the effect of miR-34a on the expression of Sca-1, Sca-1 was detected in OSCs transfected with miR-34a mimics or shSox-2 using immunofluorescence staining. Consistent with the total protein quantity of Sca-1, its distribution in OSCs was reduced by transfection with the miR-34a mimics or shSox-2 (Fig. 3A). To determine the role of miR-34a in the self-renewal capacity of osteospheres, single cell suspensions of osteospheres were harvested and incubated with LV-GFP for pre-labeling. The self-renewal capacity of the osteospheres was identified by the expression of GFP (Fig. 3B; upper panel). The number of

osteospheres measuring $\geq 40 \mu\text{m}$ in diameter, generated from a single GFP-positive primary OSC, were quantified. Compared with the OSCs transfected with scrambled miR-34a mimics or scrambled shRNA, transfection with the miR-34a mimics or shSox-2 significantly impaired the capacity of the OSCs to generate osteospheres (Fig. 3B; lower panel; $P < 0.05$ for scrambled miR-34a mimics, vs. miR-34a mimics; $P \leq 0.01$ for scrambled shRNA, vs. shSox-2). A previously study reporting the enhancement of the tumorigenic ability of osteospheres (5) promoted the assessment of the effect of miR-34a on colony formation of the OSCs. As expected, OSCs overexpressing miR-34a or shSox-2 decreased the colony formation *in vitro* (Fig. 3C and D). Taken together, these results indicated that the overexpression of miR-34a or shSox-2 markedly reduced the *in vitro* transformed phenotype of OSCs.

miR-34a upregulates the expression of osteogenic markers in OSCs. In our previous study, it was shown that miR-34a reduced tumorigenic ability, which indicated that the subsequent improvement in osteogenic differentiation was due to the homeostasis of stem cell maintenance and differentiation (6). Therefore, the present study aimed to determine whether miR-34a upregulates the transcription of osteogenic markers, Runx-2 and Collagen type I. The treated OCSs were assayed for the mRNA and protein levels of Runx-2 and Collagen type I using RT-qPCR and semiquantitative western blot analysis. As shown in Fig. 4A, the mRNA and protein levels of Runx-2 and Collagen type I were consistently higher, compared with those in the control cells. It is known that miR-34 inhibits the invasion of osteosarcoma (7), and the present study performed a Transwell invasion assay to investigate the effects of miR-34a




Figure 3. miR-34a inhibits self-renewal capacity and tumorigenic ability *in vitro*. (A) Immunostaining of the Sca-1 stem cell antigen. Magnification x200. (B) GFP⁺ osteospheres (upper panel) were counted under a contrast phase microscope. *P<0.05 and **P<0.01 (n=3). Magnification, x200. (C and D) Soft agar colony formation. Colonies measuring $\geq 40 \mu\text{m}$ in diameter were counted. *P<0.05 and **P<0.01 (n=3). miR, microRNA; Sox-2, (sex determining region Y)-box 2; Sca-1, stem cell antigen-1.




Figure 4. miR-34a upregulates the expression of osteogenic markers in human osteosarcoma cells. (A) Reverse transcription-quantitative polymerase chain reaction analysis (left) and semiquantitative western blot analysis (right) of Runx-2 and Collagen type I. Data are expressed as the mean \pm standard deviation. *P<0.05 and **P<0.01 (n=3). (B) Quantitative results of invasion ability following 24 h incubation were determined, shown as images (left) and as invaded cell numbers (right). Data are expressed as the mean \pm standard deviation. *P<0.05 (n=3). miR, microRNA; Sox-2, (sex determining region Y)-box 2; Sca-1, stem cell antigen-1; Runx-2, Runt-related transcription factor 2. Magnification, x100.

on the invasive processes of the OSCs *in vitro*. The results demonstrated that the cells transfected with miR-34a mimics or shSox-2 exhibited marked reductions in invasive ability, compared with the control cells (Fig. 4B).

Discussion

Substantial evidence has suggested that miRNAs are disordered in tumor cells and deregulated in a variety of human malignancies (19). By comparing the expression of a panel of miRNAs in clinical samples and adjacent normal tissues, a link has been established between the functions of miRNAs and oncogenesis. Certain miRNAs are downregulated in tumors, compared with normal adjacent tissues, including let-7 (let-7) in lung cancer and miR-127 in bladder cancer (20,21), whereas the opposite is found in other miRNAs, including miR-21 and miR-17-92 (22). As previous reports have demonstrated that the expression of miR-34a is significantly decreased in osteosarcoma samples, compared with adjacent normal tissues, and leads to the inhibition of proliferation and metastasis, the present study focused on miR-34a (13).

miR-34a is a member of the evolutionarily conserved miR-34 family. The inactivation and absence of miR-34a is associated with the pathogenesis of osteosarcoma. In *in vivo* and *in vitro* conditions, miR-34a inhibits the tumor growth and metastasis of osteosarcoma cells by directly targeting its direct target, c-Met. In addition to the direct targets of miR-34a, putative targets, which are correlated to tumor growth and metastasis, have been predicted using bioinformatics analysis, including B cell lymphoma 2, cyclin D1, cyclin-dependent kinase 6, E2F transcription factor 3 and Sox-2 (13). Of note, Sox-2 has been identified as an essential regulator in maintaining the self-renewal of tumor-initiating cells in osteosarcoma (14), therefore, the present study investigated the association between miR-34a, Sox-2 and osteosarcoma.

The present study aimed to identify the expression of miR-34a in the U-2OS human osteosarcoma cell line and in the OSCs derived from these cells. In addition the present study aimed to evaluate its role in the maintenance of the self-renewal capacity, proliferation and invasion of OSCs. The results provided evidence that miR-34a was critical in these physiological processes. The overexpression of miR-34a markedly reduced *in vitro* transformation properties, including invasion and colony formation in soft agar, and maintenance of self-renewal capacity. As expected, Sox-2 knockdown showed similar effects to those observed with the upregulation of miR-34a. Notably, the upregulation of miR-34a markedly decreased the expression of Sca-1, a stem cell antigen, accompanied by the absence of osteosphere formation, which is consistent with previous reports (16,23).

As miR-34a is widely expressed in mammalian cell lines and exhibits inhibitory effects on proliferation and metastasis in osteosarcoma cells, the present study hypothesized that the expression of miR-34a is different between OSCs and monolayers of U-2OS cells. It was found that OSCs derived from U-2OS cells showed significantly downregulated miR-34a and caused the subsequent post-transcriptional downregulation of Sox-2 (23), which has been identified as an oncogene targeted by miR-34a on its 3'untranslational region. These findings

demonstrated that downregulation of miR-34a is greatly associated with the malignancies of OSCs.

It has been reported that Sox-2 is critical in the self-renewal of cultured osteosarcoma cells with several functions, including regulating osteoblast differentiation (23). The results of the present study demonstrated that miR-34a regulated the self-renewal and tumorigenicity of osteosarcoma cells in a Sox-2-dependent manner. The overexpression of miR-34a and the downregulation of Sox-2 resulted in a considerable decrease in colony-forming ability and downregulation of the stem cell antigen, Sca-1.

In conclusion, the results of the present study demonstrated the effect of miR-34a on the maintenance of self-renewal of cells and in promoting invasion. miR-34a was identified to have a potential antitumorigenic effect in these tumors by inhibiting self-renewal capacity. Inhibiting Sox-2 by upregulating the expression of miR-34a in osteosarcoma may be considered as a basis for novel and effective therapeutic strategies for the treatment of these tumors.

Acknowledgements

The authors would like to thank Professor Shi H (Chengdu Institute of Biology, Chinese Academy of Sciences, Chengdu, China) for English editing and Dr Hu Q (Sichuan University, Chengdu, China) for providing the cell strain.

References

- Ek ET, Dass CR and Choong PF: Commonly used mouse models of osteosarcoma. *Crit Rev Oncol Hematol* 60: 1-8, 2006.
- Meyers PA, Schwartz CL, Krailo MD, Healey JH, Bernstein ML, Betcher D, Ferguson WS, Gebhardt MC, Goorin AM, Harris M, *et al*: Osteosarcoma: The addition of muramyl tripeptide to chemotherapy improves overall survival-a report from the Children's oncology group. *J Clin Oncol* 26: 633-638, 2008.
- Ma Y, Ren Y, Han EQ, Li H, Chen D, Jacobs JJ, Gitelis S, O'Keefe RJ, Konttinen YT, Yin G and Li TF: Inhibition of the Wnt- β -catenin and Notch signaling pathways sensitizes osteosarcoma cells to chemotherapy. *Biochem Biophys Res Commun* 431: 274-279, 2013.
- Zhang Y, Duan G and Feng S: MicroRNA-301a modulates doxorubicin resistance in osteosarcoma cells by targeting AMP-activated protein kinase α 1. *Biochem Biophys Res Commun* 459: 367-373, 2015.
- Clarke MF: Self-renewal and solid-tumor stem cells. *Biol Blood Marrow Transplant* 11 (2 Suppl 2): S14-S16, 2005.
- Ambros V: microRNAs: Tiny regulators with great potential. *Cell* 107: 823-826, 2001.
- Lewis BP, Burge CB and Bartel DP: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. *Cell* 120: 15-20, 2005.
- Krutoykh VA and Herceg Z: Oncogenic microRNAs (OncomiRs) as a new class of cancer biomarkers. *Bioessays* 32: 894-904, 2010.
- Lee YS and Dutta A: MicroRNAs in cancer. *Annu Rev Pathol* 4: 199-227, 2009.
- Baashah S and Soleimani M: The oncogenic and tumour suppressive roles of microRNAs in cancer and apoptosis. *Eur J Cancer* 47: 1127-1137, 2011.
- He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, Xue W, Zender L, Magnus J, Ridzon D, *et al*: A microRNA component of the p53 tumour suppressor network. *Nature* 447: 1130-1134, 2007.
- Hermeking H: p53 enters the microRNA world. *Cancer Cell* 12: 414-418, 2007.
- Yan K, Gao J, Yang T, Ma Q, Qiu X, Fan Q and Ma B: MicroRNA-34a inhibits the proliferation and metastasis of osteosarcoma cells both *in vitro* and *in vivo*. *PLoS One* 7: e33778, 2012.

14. Avilion AA, Nicolis SK, Pevny LH, Perez L, Vivian N and Lovell-Badge R: Multipotent cell lineages in early mouse development depend on SOX2 function. *Genes Dev* 17: 126-140, 2003.
15. Lefebvre V, Dumitriu B, Penzo-Méndez A, Han Y and Pallavi B: Control of cell fate and differentiation by Sry-related high-mobility-group box (Sox) transcription factors. *Int J Biochem Cell Biol* 39: 2195-2214, 2007.
16. Basu-Roy U, Seo E, Ramanathapuram L, Rapp TB, Perry JA, Orkin SH, Mansukhani A and Basilico C: Sox2 maintains self-renewal of tumor-initiating cells in osteosarcomas. *Oncogene* 31: 2270-2282, 2012.
17. Gritti A, Frölichsthal-Schoeller P, Galli R, Parati EA, Cova L, Pagano SF, Bjornson CR and Vescovi AL: Epidermal and fibroblast growth factors behave as mitogenic regulators for a single multipotent stem cell-like population from the subventricular region of the adult mouse forebrain. *J Neurosci* 19: 3287-3297, 1999.
18. Vanderluit JL, Ferguson KL, Nikolettou V, Parker M, Ruzhynsky V, Alexson T, McNamara SM, Park DS, Rudnicki M and Slack RS: p107 regulates neural precursor cells in the mammalian brain. *J Cell Biol* 166: 853-863, 2004.
19. Deng S, Calin GA, Croce CM, Coukos G and Zhang L: Mechanisms of microRNA deregulation in human cancer. *Cell Cycle* 7: 2643-2646, 2008.
20. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, Labourier E, Reinert KL, Brown D and Slack FJ: RAS is regulated by the let-7 microRNA family. *Cell* 120: 635-647, 2005.
21. Saito Y, Liang G, Egger G, Friedman JM, Chuang JC, Coetzee GA and Jones PA: Specific activation of microRNA-127 with down-regulation of the proto-oncogen BCL6 by chromatin-modifying drugs in human cancer cells. *Cancer Cell* 9: 435-443, 2006.
22. Chow TF, Mankaruos M, Scorilas A, Youssef Y, Girgis A, Mossad S, Metias S, Rofael Y, Honey RJ, Stewart R, *et al*: The miR-17-92 cluster is over expressed in and has an oncogenic effect on renal cell carcinoma. *J Urol* 183: 743-751, 2010.
23. Basu-Roy U, Ambrosetti D, Favaro R, Nicolis SK, Mansukhani A and Basilico C: The transcription factor Sox2 is required for osteoblast self-renewal. *Cell Death Differ* 17: 1345-1353, 2010.

RETRACTED